Live Breaking News & Updates on Cardiovascular Europe
Stay updated with breaking news from Cardiovascular europe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(0) Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48 ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) to date Data presented at the annual scientific meeting of the European Heart Rhythm Association Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety profile of LIXIANA ....
Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO - (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI - (bempedoic acid and ezetimibe) tablet approved in Switzerland (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients - - Bempedoic acid and its fixed combination drug product with ezetimibe both deliver significant reductions in LDL-C when added to a statin or other lipid-lowering therapies 1,2 - Two-thirds of patients in Switzerland with very high cardiovascular risk do not achieve LDL-C target values set out by the European Society of Cardiology, ....